My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.480 -0.030 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,575,648
Open 2.470
Bid (Size) 2.470 (18)
Ask (Size) 2.480 (1)
Prev. Close 2.510
Today's Range 2.440 - 2.520
52wk Range 0.6925 - 3.940
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 2 Health Care Stocks That May Plunge This Month
 
Via Benzinga

Performance

YTD
+12.7%
+12.7%
1 Month
+15.3%
+15.3%
3 Month
+138.5%
+138.5%
6 Month
+42.5%
+42.5%
1 Year
+52.1%
+52.1%

More News

Read More
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming September Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
Via Benzinga
What to Expect from Esperion Therapeutics's Earnings
Via Benzinga
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion (ESPR) Q2 Revenue Jumps 12%
Via The Motley Fool
Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth
Via Chartmill
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga
Esperion to Report Second Quarter 2025 Financial Results on August 5
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Craig Thompson to Board of Directors
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports First Quarter 2025 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Via Stocktwits
Topics Stocks
Esperion to Participate in The Citizens Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report First Quarter 2025 Financial Results on May 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
What is the current price of Esperion Therapeutics, Inc. - Common Stock?
The current price of Esperion Therapeutics, Inc. - Common Stock is 2.480
When was Esperion Therapeutics, Inc. - Common Stock last traded?
The last trade of Esperion Therapeutics, Inc. - Common Stock was at 09/23/25 04:00 PM ET
What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 70.13M
How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
Esperion Therapeutics, Inc. - Common Stock has 70M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.